期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 66, 期 1, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02146-21
关键词
uropathogenic Escherichia coli; antibiotic resistance; ciprofloxacin; plasmid-mediated resistance
资金
- National Health and Medical Research Council of Australia (NHMRC) [APP1181958, APP2001431]
- Galician Ministry of Culture, Education and University Planning and Galician Ministry of Economy, Employment and Industry (Regional Government of Galicia-Spain) [IN606B-2018/011]
The plasmid-associated resistance gene, AAC (6')-Ib-cr, provides a selective advantage for the dissemination of Escherichia coli ST131, a highly antibiotic resistant clone. This gene, which inactivates the fluoroquinolone antibiotic ciprofloxacin, is present in over 70% of strains from the rapidly growing subgroup of multidrug resistant ST131. The presence of this gene gives ST131 an edge even in the presence of chromosomal FQ-resistance mutations.
Escherichia coli ST131 is a recently emerged antibiotic resistant clone responsible for high rates of urinary tract and bloodstream infections. Despite its global dominance, the precise mechanisms that have driven the rapid dissemination of ST131 remain unknown. Here, we show that the plasmid-associated resistance gene encoding the AAC (6')-Ib-cr enzyme that inactivates the fluoroquinolone (FQ) antibiotic ciprofloxacin is present in >70% of strains from the most rapidly expanding subgroup of multidrug resistant ST131. Using a series of genome-edited and plasmid-cured isogenic strains, we demonstrate that the aac(6')-Ib-cr gene confers a selective advantage on ST131 in the presence of ciprofloxacin, even in strains containing chromosomal GyrA and ParC FQ-resistance mutations. Further, we identify a pattern of emerging carbapenem resistance in other common E. coli clones carrying both aac(6')-Ib-cr and chromosomal FQ-resistance mutations, suggesting this dual resistance combination may also impart a selective advantage on these non-ST131 antibiotic resistant lineages.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据